NKTR
Nektar Therapeutics·NASDAQ
--
--(--)
--
--(--)
NKTR fundamentals
Nektar Therapeutics (NKTR) released its earnings on Mar 12, 2026: revenue was 21.81M (YoY -25.25%), beat estimates; EPS was -1.78 (YoY -495.56%), beat estimates.
Revenue / YoY
21.81M
-25.25%
EPS / YoY
-1.78
-495.56%
Report date
Mar 12, 2026
NKTR Earnings Call Summary for Q4,2025
- REZPEG Phase IIb Success: Showcased durability with 5x EASI-100 improvement and monthly/quarterly dosing, positioning as novel Treg-targeting biologic.
- Market Leadership: $33B atopic dermatitis market with only 10% penetration; REZPEG Phase III to start June 2026, BLA in 2029.
- Financial Strength: $400-460M cash by end-2026; 2026 R&D spend $200-250M for Phase III.
- Alopecia Catalyst: 52-week data in April 2026; potential to match low-dose JAK efficacy with better safety profile.
- Type 1 Diabetes Expansion: Phase II with TrialNet; C-peptide preservation data expected 2027.
EPS
Actual | -11.7 | -6.75 | -9.15 | -9.75 | -10.2 | -10.35 | -10.5 | -11.85 | -7.35 | -12.75 | -4.65 | -4.8 | -10.95 | -4.05 | -3.6 | -3.3 | -2.85 | -3.75 | -2.7 | 0.45 | -3.6 | -2.95 | -1.87 | -1.78 | |||||||||||
Forecast | -11.6036 | -10.2462 | -11.3308 | -10.2042 | -11.01 | -10.9625 | -11.9705 | -12.05 | -9.4636 | -14.55 | -6.735 | -6.7791 | -3.7206 | -4.2221 | -2.9747 | -3.1566 | -2.85 | -2.775 | -2.9852 | -2.0342 | -2.5643 | -3.0276 | -2.6849 | -2.4741 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.83% | +34.12% | +19.25% | +4.45% | +7.36% | +5.59% | +12.28% | +1.66% | +22.33% | +12.37% | +30.96% | +29.19% | -194.31% | +4.08% | -21.02% | -4.54% | 0.00% | -35.14% | +9.55% | +122.12% | -40.39% | +2.56% | +30.35% | +28.05% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 50.57M | 48.85M | 30.03M | 23.46M | 23.65M | 28.33M | 24.92M | 25.01M | 24.82M | 21.59M | 23.63M | 22.02M | 21.59M | 20.50M | 24.14M | 23.89M | 21.64M | 23.49M | 24.12M | 29.18M | 10.46M | 11.18M | 11.79M | 21.81M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 48.50M | 22.76M | 22.59M | 29.86M | 25.73M | 26.15M | 28.13M | 34.26M | 24.30M | 22.62M | 22.61M | 22.14M | 19.41M | 21.79M | 21.26M | 21.43M | 15.34M | 18.20M | 19.18M | 35.50M | 15.35M | 9.49M | 10.05M | 10.19M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.28% | +114.63% | +32.96% | -21.42% | -8.08% | +8.33% | -11.42% | -27.01% | +2.16% | -4.56% | +4.50% | -0.51% | +11.25% | -5.92% | +13.54% | +11.47% | +41.05% | +29.03% | +25.81% | -17.81% | -31.87% | +17.77% | +17.26% | +114.01% |
Earnings Call
You can ask Aime
What were the key takeaways from Nektar Therapeutics’s earnings call?What factors drove the changes in Nektar Therapeutics's revenue and profit?What is Nektar Therapeutics's gross profit margin?What guidance did Nektar Therapeutics's management provide for the next earnings period?What is the revenue and EPS growth rate for Nektar Therapeutics year over year?What is Nektar Therapeutics's latest dividend and current dividend yield?What does Nektar Therapeutics do and what are its main business segments?Did Nektar Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
